<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443274</url>
  </required_header>
  <id_info>
    <org_study_id>BIFS001</org_study_id>
    <nct_id>NCT00443274</nct_id>
  </id_info>
  <brief_title>Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms</brief_title>
  <acronym>BIFS</acronym>
  <official_title>Breast Implant Follow-up Study: A Long-term Observational Study of the Safety of Allergan Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms (410-arm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ten year safety study examining rates of rare adverse events, child bearing issues, effects&#xD;
      of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast&#xD;
      implants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2006</start_date>
  <completion_date type="Anticipated">July 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 21, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk rates of adverse events of high clinical interest (eg, cancers, neurological diseases, connective tissue diseases) assessed by the investigator</measure>
    <time_frame>10 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk rates of common complications of breast surgery (eg, capsular contracture, implant rupture/deflation) assessed by the subject and investigator</measure>
    <time_frame>10 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-operations</measure>
    <time_frame>10 Years</time_frame>
    <description>Rates of reoperation reported by subjects and by investigators at office visits</description>
  </primary_outcome>
  <enrollment type="Anticipated">56460</enrollment>
  <condition>Breast Implant</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NBIR - US National Breast Implant Registry</intervention_name>
    <description>NBIR is intended to be a surveillance tool to track patient safety and real-world outcomes associated with breast implants used for aesthetic or reconstructive purposes..</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>410 Arm</intervention_name>
    <description>Anatomically shaped silicone gel-filled breast implants.</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIFs - Breast Implant Follow-Up Study</intervention_name>
    <description>Round silicone gel-filled breast implants and saline-filled breast implants</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with breast implants for augmentation, reconstruction, or revision of augmentation or&#xD;
        reconstruction&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Screening Criteria&#xD;
&#xD;
          1. Female&#xD;
&#xD;
               1. age 18 years or older who is a candidate for breast reconstruction (primary or&#xD;
                  revision) with Allergan silicone implants or saline breast implants (controls) OR&#xD;
&#xD;
               2. age 22 or older who is a candidate for breast augmentation (primary or revision)&#xD;
                  with Allergan silicone implants or saline breast implants (controls)&#xD;
&#xD;
          2. Exhibit fluency and literacy in English or Spanish&#xD;
&#xD;
        Enrollment Criteria&#xD;
&#xD;
          1. Have satisfied all the inclusion and none of the exclusion criteria&#xD;
&#xD;
          2. Have completed the implant surgery&#xD;
&#xD;
          3. Have only one breast implant or have matching breast implants (i.e., both Round&#xD;
             Responsive, both Style 410, or both saline) following their qualifying surgery. In the&#xD;
             case of silicone, the device(s) must be manufactured by Allergan.&#xD;
&#xD;
          4. Are free of all target diseases at baseline (410 arm only)&#xD;
&#xD;
          5. Have signed the informed consent form, documenting agreement to participate in all&#xD;
             required follow-up interviews by internet, phone, or mail and authorizing health care&#xD;
             providers to release medical records to study personnel, and have completed the&#xD;
             baseline questionnaire prior to implant surgery (prospectively enrolled subjects)&#xD;
&#xD;
        For retrospectively enrolled subjects into the 410 arm, in addition to the above, these&#xD;
        criteria also apply:&#xD;
&#xD;
          1. Received 1 or 2 Style 410 implants between 2015 and 2019&#xD;
&#xD;
          2. Willing to complete baseline questionnaire at time of enrollment&#xD;
&#xD;
        Continuation Criteria (BIFS Arm Only)&#xD;
&#xD;
          1. Have completed baseline and years 1, 2, 3 and 4 follow-up questionnaires available&#xD;
             (including the Satisfaction with Breasts and Psychosocial Well-Being modules of the&#xD;
             BREAST-Q)&#xD;
&#xD;
          2. Met all enrollment criteria, specifically the minimum age requirements for silicone&#xD;
             implants (18 or older for reconstruction subjects and 22 or older for augmentation&#xD;
             subjects), and were free of all target diseases at baseline&#xD;
&#xD;
          3. Were enrolled at a site that was selected in the cluster sampling to continue in the&#xD;
             BIFS arm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Are transgender&#xD;
&#xD;
          2. If a saline implant subject, have a current or past unilateral or bilateral silicone&#xD;
             gelfilled breast implant&#xD;
&#xD;
          3. Investigator decision that subject is not a suitable candidate for a long-term&#xD;
             observational study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southwest Plastic Surgery /ID# 240510</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925-7618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2007</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

